Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash & Equivalents (2016 - 2026)

Ekso Bionics Holdings has reported Cash & Equivalents over the past 14 years, most recently at $2.7 million for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 67.17% to $2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.7 million, a 67.17% decrease, with the full-year FY2024 number at $2.0 million, down 76.85% from a year prior.
  • Cash & Equivalents reached $2.7 million in Q3 2025 per EKSO's latest filing, down from $5.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $49.5 million in Q1 2021, with the low at $2.0 million in Q4 2024.
  • The 5-year median for Cash & Equivalents is $13.3 million (2023), against an average of $20.3 million.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 481.72% in 2021, then crashed 76.85% in 2024.
  • Tracing EKSO's Cash & Equivalents over 5 years: stood at $40.4 million in 2021, then tumbled by 49.2% to $20.5 million in 2022, then crashed by 57.91% to $8.6 million in 2023, then crashed by 76.85% to $2.0 million in 2024, then skyrocketed by 36.1% to $2.7 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $2.7 million, $5.2 million, and $8.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.